Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome

被引：3

作者：

Gianotti, N ^{[1
]}

Soria, A ^{[1
]}

Galli, L ^{[1
]}

Giudici, B ^{[1
]}

Fusetti, G ^{[1
]}

Lazzarin, A ^{[1
]}

Boeri, E ^{[1
]}

Castagna, A ^{[1
]}

机构：

[1] Univ Vita Salute San Raffaele, Clin Infect Dis, Milan, Italy

来源：

AIDS | 2004年 / 18卷 / 05期

关键词：

D O I：

10.1097/00002030-200403260-00018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The best salvage therapy for protease inhibitor (PI)-resistant HIV-infected patients is still controversial. We measured changes in viral load and CD4 T-lymphocyte counts in 40 PI-resistant patients receiving boosted PI-including or PI-sparing antiretroviral therapy. At multivariate analysis, the only independent predictor of CD4 T-lymphocyte changes at week 24 was a boosted PI-including regimen. In PI-resistant HIV-infected patients, a boosted PI regimen preserves CD4 T lymphocytes from depletion in the medium term compared with a PI-sparing regimen.

引用

页码：821 / 823

页数：3

共 50 条

[1] Protease inhibitor-sparing regimen suppresses HIV
不详
[J]. AIDS PATIENT CARE AND STDS, 1998, 12 (12) : 940 - 940
[2] Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children
Pensieroso, Simone
Romiti, Maria Luisa
Palma, Paolo
Castelli-Gattinara, Guido
Bernardi, Stefania
Freda, Elio
Rossi, Paolo
Cancrini, Caterina
[J]. AIDS, 2006, 20 (14) : 1893 - 1896
[3] Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients
Gilliam, Bruce L.
Chan-Tack, Kirk M.
Qaqish, Roula B.
Rode, Richard A.
Fantry, Lori E.
Redfield, Robert R.
[J]. AIDS PATIENT CARE AND STDS, 2006, 20 (11) : 745 - 759
[4] Evaluation of Lipid Profile and Intima Media Thickness in Antiretroviral-Experienced HIV-Infected Patients Treated with Protease Inhibitor-Based Regimens versus Protease Inhibitor-Sparing Regimens
Martini, Salvatore
Pisaturo, Mariantonietta
Russo, Antonio
Palamone, Maria Grazia
Russo, Maria Teresa
Zollo, Verdiana
Maggi, Paolo
Coppola, Nicola
[J]. PATHOGENS, 2023, 12 (07):
[5] Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
Gianotti, N
Seminari, E
Lazzarin, A
Boeri, E
Clementi, M
Danise, A
Salpietro, S
Fusetti, G
Castagna, A
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (06) : 545 - 554
[6] Darunavir: an effective protease inhibitor for HIV-infected patients
Phung, Bao-Chau
Yeni, Patrick
[J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (06) : 631 - 643
[7] Protease inhibitor therapy in HIV-infected children
Feingold, AR
Rutstein, RM
Meislich, D
Brown, T
Rudy, BJ
[J]. AIDS PATIENT CARE AND STDS, 2000, 14 (11) : 589 - 593
[8] Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience
Nozza, Silvia
Galli, Laura
Visco, Francesca
Soria, Alessandro
Canducci, Filippo
Salpietro, Stefania
Gianotti, Nicola
Bigoloni, Alba
Della Torre, Liviana
Tambussi, Giuseppe
Lazzarin, Adriano
Castagna, Antonella
[J]. AIDS, 2010, 24 (06) : 924 - 928
[9] The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen
Leitz, G
Robinson, P
[J]. AIDS, 2000, 14 (04) : 468 - 469
[10] Evolution of human immunodeficiency virus type-1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
Gianotti, N
Seminari, E
Lazzarin, A
Boeri, E
Clementi, M
Danise, A
Salpietro, S
Fusetti, G
Castagna, A
[J]. ANTIVIRAL THERAPY, 2004, 9 (04) : U66 - U66

← 1 2 3 4 5 →